Some studies have shown a causal relationship between those treated with IFN-β and incidence of FSGS.[27–29] The incidence of FSGS in these patients cannot be directly attributed to MS, but rather to the use of interferon-gamma, whose side effects are dependent on dose, treatment duration, and presence of comorbidities such as diabetes mellitus and hypertension.[11]. The gene discussed is IFNB1; the disease is myeloid sarcoma.